Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.

Initial cytoreductive nephrectomy prolongs OS in metastatic renal cell carcinoma

15 Dec 2017

Initial cytoreductive nephrectomy (CN) provides overall survival (OS) advantage in metastatic renal cell carcinoma (mRCC) compared with initial systemic therapy, a recent study reports.

Drawing data from the Surveillance, Epidemiology and End Results registries, researchers looked at 537 elderly patients (>65 years of age) with mRCC. They conducted sequential survival analysis to evaluate the effect of initial CN on OS, as well as instrumental variable analysis to account for measured and unmeasured selection bias.

Of the patients, 190 underwent initial CN followed by targeted therapy and 347 received initial targeted therapy.

Median OS was 17.4 months (IQR, 9.8 to 32.0) in the initial CN group compared with 9.2 months (IQR 4.3 to 18.0) in the initial targeted therapy group. On Cox proportional hazards analysis, initial CN improved OS by 50 percent (95 percent CI, 0.38 to 0.65). Propensity score matching showed that initial CN was associated with a survival advantage of 5.8 months (1.9 to 9.7).

In an analysis accounting for confounding, only a trend toward improved survival with initial CN (hazard ratio, 0.29; 0.08 to 1.00) was observed.

The improved OS observed with initial CN notwithstanding, researchers noted that selection for CN in the contemporary mRCC era might be confounded by regional variation and influenced by provider uncertainty. They highlighted the need for prospective randomized controlled trials to definitively address this clinical conundrum.

Current consensus-based guidelines recommend CN in carefully selected mRCC patients with a disease that can be managed with surgical resection. This is based on high-level evidence of CN with cytokine therapy and supported by retrospective cohort studies of CN with contemporary therapies. [Eur Urol 2015;67:913-924; J Natl Compr Canc Netw 2015;13:151-159]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.